A Profile of Huada Life Science Development Group Co., Ltd
Huada Life Science Development Group is a joint venture controlled by Baida Finance Group Co., Ltd. Huada's aim is to devote itself to the research, development, and application of human life science.
It owns a team of first-class experts and excellent technical personnel. The experts have taken out many patents for their inventions. The group has established laboratories, clinical laboratory center, special test center, and specimen bank in Beijing.
Main products of Huada Life Science Group are listed as follows:
1. The isolation and application of hypoxia-inducible peptide (HIP) as a therapeutic drug and healthcare products;
2. Specific diagnostic kit (HE4 ELISA) for ovarian and endometrial cancers;
3. Diagnostic kit for cervical cancer (IER 5 monoclonal antibody);
4. A complete new early diagnostic kit for Parkinson's disease;
5. Protein markers diagnostic kit for aging-related diseases (Parkinson's disease);
6. Ten antibodies for Normal research and histological diagnosis;
7. Platform setup for tumor molecular diagnostic technology;
Life science is a core department of sciences in the 21st century.
Hypoxic Inducible Peptide is a world-leading innovation program, which was proposed and verified based on the adaptability prevailing in animal kingdom to the environmental changes. The project team has found £¬first in the world, by using animal models, a material-HIP£¬which can reduce the metabolic rate and enhance the anti-hypoxia and anti-tumor ability. HIP could markedly increase the hypoxic tolerance of an animal by decreasing his metabolic rate. These hypoxia resistance measures are different from the currently existing ones of anti-hypoxia injures by increasing oxygen intake or preventing hypoxia injured pathological cascade, for the hypoxia resistance effect of the latter is quite limited. However, the measures to markedly increase the hypoxic tolerance of an animal by decreasing his metabolic rate imitate the measures to adapt to extreme oxygen deprivation by some extreme anti-hypoxia animals (for example: freshwater turtle) and newborn animals, thus markedly enhancing an animal's hypoxia resistance. In the meanwhile, the research team has found that HIP components can inhibit tumor growth by inhibiting the cycles of tumor cells. The results of animal test show that it has obvious anti-tumor effect without significant side effects. Therefore, HIP will become an important candidate for the new-generation of anti-tumor biologicals. Since suppressing metabolic rate is generally acknowledged by the academic circle as an effective strategy to slow down aging and aging-related disease, HIP therefore can be developed into related drugs and healthcare products to open a new path for human longevity and disease prevention and control. HIP has won experts¡¯ authentication of experts on May 16, 2010.
In the late 1990s, the first draft of the human genome was completed and since then the genomics has undergone explosive growth. This unprecedented life science project brings people great hope and longing in early in-vitro diagnosing and preventing critical illness like tumor. In the post-genome era, the dramatically advancing researches on in-vitro diagnostic methods are getting more and more mature. Some of the proteomic and genomic instruments have been applied to clinical stage of disease diagnosis. These diagnostic reagents and methods which are based on genetic information will help doctors make diagnosis faster and more accurately. The treatment will be more pertinent and cost-effective. Such molecular diagnosis on the basis of applied genomics will exert a great influence on the future of medical service, esp. on the early diagnosis of disease, thus realizing humanity's long-cherished dream of detecting disease before it comes into being. In spite of the precarious Wall Street financial market and the unpromising credit crisis several years ago, those life science-related biological technology stocks remained robust, esp. those of in-vitro diagnostic technology. The advanced technologies on early diagnosis and screening of dread diseases are much sought-after by investors and big pharmaceutical factories. Since early-stage and clinical diagnoses will prove to be of great use and advantage in the medical field and in the customized diagnosis and treatment, so that it is predicted that more and more research and development funds and resources will be diverted from medical development to disease diagnosis.
The research group has reached a new stage in the field of proteomic and genomic clinical diagnostic reagents. On one hand, it has applied some modern biological technologies, such as those of genetic recombination and monoclonal antibodies, and it has greatly integrated and automated the production process. On the other hand, it made these technologies easy and fast to popularize. These precise diagnostic reagents have been effective in disease prevention, treatment, post-diagnosis, therapeutic drug monitoring, evaluation of health and hereditary prediction. To date, some of these technologies have been patented and some of them are in the process of application. The commercial and investment value of these technologies is increasingly growing. More and more people will benefit from them.
